Omnicell (NASDAQ:OMCL) Rating Lowered to “Hold” at StockNews.com

Omnicell (NASDAQ:OMCL) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

A number of other equities research analysts have also recently issued reports on the stock. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Bank of America restated a “neutral” rating and set a $57.00 target price (up previously from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Wells Fargo & Company boosted their price target on Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Craig Hallum raised their price objective on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Benchmark reissued a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Omnicell has a consensus rating of “Hold” and a consensus target price of $52.00.

Omnicell Stock Down 0.3 %

Shares of NASDAQ:OMCL opened at $47.01 on Tuesday. Omnicell has a 12-month low of $25.12 and a 12-month high of $55.74. The business has a 50 day moving average of $45.16 and a 200-day moving average of $38.85. The stock has a market cap of $2.18 billion, a PE ratio of -120.54, a P/E/G ratio of 34.95 and a beta of 0.77.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently made changes to their positions in the business. Franklin Resources Inc. raised its stake in Omnicell by 49.9% during the 3rd quarter. Franklin Resources Inc. now owns 30,807 shares of the company’s stock worth $1,316,000 after buying an additional 10,260 shares during the period. Geode Capital Management LLC grew its holdings in Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after buying an additional 2,877 shares in the last quarter. Pier Capital LLC bought a new stake in shares of Omnicell in the 3rd quarter worth $5,859,000. SageView Advisory Group LLC purchased a new stake in Omnicell in the 3rd quarter valued at about $480,000. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in Omnicell by 27.1% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after acquiring an additional 243,353 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.